曹仁发三步推拿法治疗失眠临床疗效观察

目的观察曹仁发教授的三步推拿法治疗失眠的临床疗效。方法将90例失眠患者随机分为安定组、推拿组和结合组(各30例),分别给予舒乐安定片口服和(或)曹仁发三步推拿法治疗,疗程12天。观察三组临床疗效和治疗前后匹兹堡睡眠质量指数量表(PSQI)评分、阿森斯失眠量表(AIS)评分和多导睡眠图结果变化。结果 (1)安定组总有效率为83.30%,推拿组为80.00%,结合组为93.30%;结合组临床疗效优于安定组和推拿组(P0.05)。(2)治疗后,三组PSQI和AIS评分均较治疗前明显降低(P0.05),且结合组低于安定组和推拿组(P0.05)。(3)治疗后,三组浅睡眠时间及深睡眠时间均较治疗前显著延长(P0.05),且结合组长于安定组和推拿组(P0.05)。结论曹仁发三步推拿法可显著改善失眠患者的睡眠质量。     

MiR-130b attenuates vascular inflammation via negatively regulating tumor progression locus 2 (Tpl2) expression

Endothelial cell (EC) activation and dysfunction have been linked to a wide variety of vascular inflammatory diseases. However, the role of microRNAs in EC activation and inflammation remains largely unknown. In this study, we found that miR-130b was significantly decreased in human umbilical vein endothelial cells (HUVECs) after lipopolysaccharides (LPS) treatment. Forced expression of miR-130b inhibited the LPS-induced activation of extracellular signal-regulated kinase (ERK) and the inflammatory genes expression, such as interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α). Furthermore, we identified that tumor progression locus 2 (Tpl2) is a direct target of miR-130b. Finally, in vivo overexpression of miR-130b via miR-130b agomir attenuates acute lung vascular inflammation in the LPS-induced sepsis mouse model. Taken together, our data demonstrated that miR-130b represses vascular inflammation via targeting Tpl2, suggesting that miR-130b mimics might be a promising therapeutic strategy for treatment of vascular inflammatory diseases.     

Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine

Clinical trial outcome reporting differs between studies integrating traditional Chinese medicine (TCM) and Western medicine, so that some clinical trials are not eligible for inclusion in a systematic review. The excluded studies are therefore less widely disseminated, and even valid studies are less likely to yield impact. This problem may be addressed by developing core outcome sets (COSs) for integrative medicine in specific healthcare areas. The first stage of development is to define the scope of the COS for integrative medicine, the second stage is to establish the need for such a COS, and the third stage is to develop a protocol and register the COS. The final stage involves three steps: (i) development of a comprehensive list of outcomes (including efficacy outcomes and safety outcomes and TCM syndromes) using systematic review, qualitative or cross-sectional research, and reviews of package inserts and medical records; (ii) merging and grouping of outcomes within domains; (iii) conducting two rounds of Delphi survey and consensus meetings with a range of stakeholders. The final COS will include a general COS and core TCM syndrome- set. Development of COSs for clinical trials of integrative medicine may help to standardize outcome reporting and reduce publication bias in the future.     

Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention

The gut microbiota plays an important role in the occurrence and development of neuroimmunological diseases. Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system that is characterized by the peripheral production of the disease-specific serum autoantibody aquaporin-4 (AQP4)-IgG. Recently, accumulating evidence has provided insights into the associations of gut microbiota dysbiosis and intestinal mucosal barrier destruction with NMOSD, but the underlying pathogenesis remains unclear. Thus, a microbiota intervention might be a potential therapeutic strategy for NMOSD by regulating the gut microbiota, repairing the intestinal mucosal barrier, and modulating intestinal immunity and peripheral immunity.     

从瘀论治子宫肌瘤

子宫肌瘤患者均以手术治疗为主,但由于手术所致的创伤和相关并发症,使近年来许多子宫肌瘤患者选择非手术治疗,而中医在治疗子宫肌瘤上又有肯定优势,其中根据其病因病机,以扶正祛瘀为治疗大法,在临床上取得了良好疗效.本文主要就中医治疗子宫肌瘤进行分析,总结从瘀论治子宫肌瘤的进展.     

左乙拉西坦缓释片在Beagle犬中的生物等效性研究

目的以Beagle犬为模型考察自制左乙拉西坦缓释片与参比缓释片(Keppra XR)在动物体内的生物等效性。方法 Beagle犬分别单剂量口服自制缓释片与参比制剂1 000mg,采用LC-MS/MS方法测定犬血浆中左乙拉西坦的浓度,通过药代动力学计算软件WinNonlin 5.2以非房室模型分别计算左乙拉西坦的药代动力学参数。结果自制缓释片与市售参比缓释片单剂量口服后,左乙拉西坦的达峰时间tmax分为1.67h和3.0h;峰浓度Cmax分别为89.50μg/ml和71.18μg/ml;消除半衰期t1/2分别为3.68h和3.50h;药时曲线下面积AUC(0-48)分别为826.57μg·h/ml和757.84μg·h/ml;药时曲线下面积AUC(0-∞)分别为826.68μg·h/ml和757.93μg·h/ml。与参比缓释片相比,自制左乙拉西坦缓释片的相对生物利用度为109.07%。结论初步判定两种制剂在犬体内具有类似的药代动力学特征和生物等效性。     

中药治疗糖尿病难愈性创面愈合的研究进展

摘 要 难愈性创面是糖尿病的常见并发症,目前糖尿病难愈性创面及其治疗手段引起人们的广泛关注。本文就中药对糖尿病创面愈合的影响从促进成纤维细胞的增殖、促进肉芽组织生成、增加生长因子分泌、减少创面瘢痕及临床研究等方面进行了系统综述,以期为中药治疗难愈性创面愈合提供科学依据。     

三种不同严重程度大鼠重症胰腺炎模型比较研究

目的 为研究者选择合适的牛磺胆酸钠浓度来制备大鼠重症胰腺炎(severe acute pancreatitis,SAP)SAP模型提供依据。方法 将60只SD大鼠随机分为假手术组、1.5%浓度组、3.5%浓度组和5%浓度组, 造模各组分别用1.5%、3.5%和5%牛磺胆酸钠按逆行胆胰管注射法制备SAP模型。术后统计各组大鼠的死亡率;检测血清淀粉酶、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平;观测各组大鼠胰腺组织HE染色病理评分。结果 5%浓度组死亡率较1.5%浓度组显著升高, 血淀粉酶、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平、出血和腺泡组织坏死的病理评分较1.5%浓度组和3.5%浓度组均有显著升高。结论 5%的牛磺胆酸钠逆行胆胰管注射法能更好的制备SAP模型, 且更符合SAP的生理、病理表现。     

便秘患者的特征及中药治疗用药归经特点分析

目的析便秘患者治疗中的中医用药归经特点,为规范便秘患者中医治疗方案提供参考依据。方法采用描述流行病学方法,收集2018年1月至2018年12月上海中医药大学附属岳阳中西医结合医院健康信息系统(health information system,HIS)中诊断为便秘的患者信息,应用SPSS16.0统计软件对便秘患者的一般人口学特征、药物频次及归经特点进行描述、分析。结果本研究共纳入便秘患者12786例,其中男性5043例(39.44%),患者年龄0~100岁,中位年龄64岁。12786例患者中,5623例患者接受纯中药治疗(43.98%),3788例患者接受中西医联合治疗(29.63%)。接受中药治疗的9411例患者中,5487例使用了中药饮片(58.30%),中药饮片使用频数排名前五位的药物为甘草、白术、火麻仁、枳实及厚朴。中药的归经分析显示药味归经均数排名前五为脾、胃、肺、大肠及心。女性患者使用中药归经为"肝"的多于男性患者。结论便秘患者的中药治疗以固护脾胃为主,通调肺、肠为辅;对于女性便秘患者,用药多投以肝经药味。     

中药辅助紫杉醇

【摘要】 目的 评价中药辅助紫杉醇- 顺铂（TP）方案经导管动脉灌注化疗（TAI）治疗不可切除非小细胞肺癌（NSCLC）的临床价值。方法 随访连续103例NSCLC患者,按治疗方法不同分为接受TAI治疗的西医组和接受中药辅助TAI治疗的中西医组。结果 103例肺癌患者西医组71例,中西医组32例。西医组的平均生存期为10.5个月,中西医组的平均生存期为15.5个月;西医组的中位生存期为7.0个月,中西医组的中位生存期为12.0个月。西医组的6个月、1年、2年生存率分别为64.8%、26.8%、8.5%,中西医组分别为71.9%、43.8%、18.8%。中西医组的总生存期、平均生存期、中位生存期及生存率（6个月、1年和2年生存率）均高于西医组,差异有统计学意义（P＜0.05）。结论 中药辅助TAI治疗能延长不可切除NSCLC患者的生存期,提高患者的生存率,改善患者的生存质量,并降低患者的介入化疗后的不良反应,是一种安全有效的肺癌治疗模式。